Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-6 (Canceled).

7. (Previously presented) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, the method comprising the following steps, in the following order:

(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence comprising R_1 - R_2 - R_3 - R_4 - R_5 - R_6 - R_7 - R_8 - R_9 - R_{10} - R_{11} - R_{12} - R_{13} - R_{14} - R_{15} - R_{16}, wherein R_1 is Gln, Lys, or Arg; R_2 is Arg; R_3 and R_4 are members independently selected from the group consisting of all amino acids; R_5 is Ala, Glu, Asp, Val, Leu or Ile; R_6 and R_7 are members independently selected from the group consisting of all amino acids; R_8 is Thr; R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, and R_{15} are members independently selected from the group consisting of all amino acids; and, R_{16} is Val (SEQ ID NO:2),

(b) amplifying the nucleic acid; and

(c) detecting the amplified nucleic acid.

8. (Previously presented) The method of claim 7, wherein the MHC nucleic acid is HLA-DR 10.

9. (Previously presented) The method of claim 7, wherein the subsequence encodes a peptide wherein R_1 is Gln, Lys, or Arg; R_2 is Arg; R_3 is Arg; R_4 is Ala; R_5 is Ala; R_6 is Val; R_7 is Asp; R_8 is Thr; R_9 is Tyr; R_{10} is Cys; R_{11} is Arg; R_{12} is His; R_{13} is Asn; R_{14} is Tyr; R_{15} is Gly, and R_{16} is Val (SEQ ID NO:2).

10. (Original) The method of claim 7, wherein the biological sample comprises a B cell.

11. (Original) The method of claim 10, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.

12. (Original) The method of claim 11, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALTL) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.

13 (Original) The method of claim 7, wherein the biological sample is a body fluid sample or a biopsy sample.

14. (Original) The method of claim 13, wherein the body fluid sample is a blood sample.

15-34. (Canceled)

35. (Previously presented) A method for detecting a nucleic acid in a biological sample, wherein the nucleic acid encodes a peptide capable of specifically binding to a Lym-1 antibody, the method comprising the following steps, performed in the following order:

(a) contacting the sample with an oligonucleotide primer pair capable of amplifying a subsequence of an MHC nucleic acid, which subsequence encodes a polypeptide having a sequence consisting essentially of R_1 - R_2 - R_3 - R_4 - R_5 - R_6 - R_7 - R_8 - R_9 - R_{10} - R_{11} - R_{12} - R_{13} - R_{14} - R_{15} - R_{16}, wherein R_1 is Gln, Lys, or Arg; R_2 is Arg; R_3 and R_4 are members independently selected from the group consisting of all amino acids; R_5 is Ala, Glu,

Asp, Val, Leu or Ile; R_6 and R_7 are members independently selected from the group consisting of all amino acids; R_8 is Thr; R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, and R_{15} are members independently selected from the group consisting of all amino acids; and, R_{16} is Val (SEQ ID NO:2),

(b) amplifying the nucleic acid; and

(c) detecting the amplified nucleic acid.

36. (Previously presented) A method of claim 35, wherein the MHC nucleic acid is HLA-DR 10.

37. (Previously presented) The method of claim 35, wherein the subsequence encodes a peptide wherein R_1 is Gln, Lys, or Arg; R_2 is Arg; R_3 is Arg; R_4 is Ala; R_5 is Ala; R_6 is Val; R_7 is Asp; R_8 is Thr; R_9 is Tyr; R_{10} is Cys; R_{11} is Arg; R_{12} is His; R_{13} is Asn; R_{14} is Tyr; R_{15} is Gly, and R_{16} is Val (SEQ ID NO:2).

38. (Previously presented) The method of claim 35, wherein the biological sample comprises a B cell.

39. (Previously presented) The method of claim 38, wherein the B cell is a B lymphocytic non-Hodgkin's lymphoma cell.

40. (Previously presented) The method of claim 39, wherein the non-Hodgkin's lymphoma cell is selected from the group consisting of a B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CCL/SLL) cell, a lymphoplasmacytoid lymphoma (LPL) cell, a follicular lymphoma (FL) cell, a mucosa-associated lymphoid tissue lymphoma (MALTL) cell, a splenic lymphoma with villous lymphocytes (SLVL) cell and a mantle cell lymphoma cell.

41. (Previously presented) The method of claim 35, wherein the biological sample is a body fluid sample or a biopsy sample.

42 (Previously presented) The method of claim 41, wherein the body fluid sample is a blood sample.

43-45. (Canceled)